Determining stationary-state quantum properties directly from system-environment interactions

Considering stationary states of continuous-variable systems undergoing an open dynamics, we unveil the connection between properties and symmetries of the latter and the dynamical parameters. In particular, we explore the relation between the Lyapunov equation for dynamical systems and the steady-state solutions of a time-independent Lindblad master equation for bosonic modes. Exploiting bona-fide relations that characterize some genuine quantum properties (entanglement, classicality, and steerability), we obtain conditions on the dynamical parameters for which the system is driven to a steady-state possessing such properties. We also develop a method to capture the symmetries of a steady state based on symmetries of the Lyapunov equation. All the results and examples can be useful for steady-state engineering process.Comment: 12 pages, 2 figure

EFEITO DE BIOPARTÍCULAS DE SÍLICA OBTIDAS DE CASCA DE ARROZ NO TRATAMENTO DA MADEIRA DE Pinus elliottii

Produtos de origem renovável podem garantir a sustentabilidade ambiental, a saúde humana, e diminuir a utilização de produtos tradicionais que possuem compostos tóxicos na sua formulação. Diante disso a pesquisa teve como objetivo avaliar a resistência biológica da madeira de Pinus elliottii contra fungos e cupins xilófagos por meio de impregnação com biopartículas de sílica (SiO2) obtidas da casca de arroz. Para a obtenção da sílica o material passou por tratamento químico, dois ciclos de lixiviação ácida com ácido clorídrico, e tratamento térmico de 500, 550 ou 600ºC. A pureza da sílica obtida foi caracterizada por fluorescência de Raios-X, e o tamanho médio das partículas por microscopia eletrônica de varredura - MEV. O SiO2 foi aplicado nos corpos de prova nas concentrações de 0,5, 1,0 e 2,0% e as amostras impregnadas submetidas aos ensaios com fungos de podridão parda (Gloeophyllum trabeum, Postia placenta e Neolentinus lepideus), podridão mole e a cupins xilófagos (Nasutitermes corniger e Cryptotermes brevis). Os tratamentos térmicos promoveram a obtenção de biopartículas de elevada pureza, com valor médio de aproximadamente 90% e diâmetro médio de 263,7 nm. No ensaio de térmitas, as menores perdas de massa e desgaste foram para as amostras impregnadas. A mortalidade dos cupins aumentou com o incremento da concentração das soluções. O SiO2 não apresentou eficiência contra os fungos xilófagos, sem diferença entre os tratamentos e as testemunhas, indicando que resistência observada foi inerente da própria madeira. Palavras-chave: Durabilidade da madeira, tratamento alternativo, biossílica

Thermal transport in out of equilibrium quantum harmonic chains

We address the problem of heat transport in a chain of coupled quantum harmonic oscillators, exposed to the influences of local environments of various nature, stressing the effects that the specific nature of the environment has on the phenomenology of the transport process. We study in detail the behavior of thermodynamically relevant quantities such as heat currents and mean energies of the oscillators, establishing rigorous analytical conditions for the existence of a steady state, whose features we analyse carefully. In particular we assess the conditions that should be faced to recover trends reminiscent of the classical Fourier law of heat conduction and highlight how such a possibility depends on the environment linked to our system.Comment: 11 pages, 15 figure

WKB Propagation of Gaussian Wavepackets

We analyze the semiclassical evolution of Gaussian wavepackets in chaotic systems. We prove that after some short time a Gaussian wavepacket becomes a primitive WKB state. From then on, the state can be propagated using the standard TDWKB scheme. Complex trajectories are not necessary to account for the long-time propagation. The Wigner function of the evolving state develops the structure of a classical filament plus quantum oscillations, with phase and amplitude being determined by geometric properties of a classical manifold.Comment: 4 pages, 4 figures; significant improvement

Weak values of a quantum observable and the cross-Wigner distribution

We study the weak values of a quantum observable from the point of view of the Wigner formalism. The main actor is here the cross-Wigner transform of two functions, which is in disguise the cross-ambiguity function familiar from radar theory and time-frequency analysis. It allows us to express weak values using a complex probability distribution. We suggest that our approach seems to confirm that the weak value of an observable is, as conjectured by several authors, due to the interference of two wavefunctions, one coming from the past, and the other from the future.Comment: Submitted for publicatio

Comparação de índices reprodutivos com diferentes dispositivos de progesterona em programa de IATF.

As biotecnologias utilizadas na reprodução animal contribuem para o melhoramento do rebanho e aumento dos índices reprodutivos. A biotécnica mais utilizada no Brasil é a Inseminação Artificial em Tempo Fixo (IATF), que consiste na sincronização de cio das fêmeas pelo uso de fármacos. Dispositivos liberadores de progesterona são utilizados nesses protocolos, existindo variedades com concentrações diferentes de princípio ativo. Logo, objetivou-se avaliar a eficiência de protocolos de IATF com diferentes dispositivos liberadores de progesterona. Foram submetidas à IATF 307 vacas divididas em cinco lotes de manejo, no período de outubro/2018 a janeiro/2019

Como implementar inseminação artificial em tempo fixo em sua fazenda : conheça os pontos-chave.

A adoção da inseminação artificial em tempo fixo (IATF) é a biotecnologia aplicada à reprodução animal que mais aumentou em 10 anos, passando de 8%, em 2012, para 18%, em 2021. Em 2022, espera-se um aumento de mais de 20%. Com objetivo de salientar os principais fatores que influenciam no bom resultado dessa biotécnica, esta cartilha foi confeccionada para que o produtor pudesse entender e avaliar, dentro de sua realidade, a viabilidade do investimento nessa prática. Os pontos abordados e as fotos mostradas servem para compartilhar nossas experiências a fim de contribuir para uma adoção segura e satisfatória da técnica pelo produtor

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.

PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS: This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS: A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E). CONCLUSION: TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC

Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer:Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study

PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).CONCLUSION TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.</p